98 related articles for article (PubMed ID: 16613764)
61. The complex role of IL-10 in malignant ascites: a review.
Huang Y; Zou K; Jiang H; Li Z
Cancer Immunol Immunother; 2024 Jan; 73(2):32. PubMed ID: 38279997
[TBL] [Abstract][Full Text] [Related]
62. CD137 Costimulation Enhances the Antitumor Activity of Vγ9Vδ2-T Cells in IL-10-Mediated Immunosuppressive Tumor Microenvironment.
Pei Y; Xiang Z; Wen K; Tu CR; Wang X; Zhang Y; Mu X; Liu Y; Tu W
Front Immunol; 2022; 13():872122. PubMed ID: 35784354
[TBL] [Abstract][Full Text] [Related]
63. Myeloid-Derived Suppressor Cells Promote Metastasis in Breast Cancer After the Stress of Operative Removal of the Primary Cancer.
Ma X; Wang M; Yin T; Zhao Y; Wei X
Front Oncol; 2019; 9():855. PubMed ID: 31552179
[No Abstract] [Full Text] [Related]
64. Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma.
Cao Y; Liu Z; Wu W; Qian Y; Shi Q; Shen R; Ouyang B; Xu P; Cheng S; Ye J; Lu Y; Wang C; Yang C; Wang L; Zhao W
Front Med; 2019 Feb; 13(1):94-103. PubMed ID: 30706260
[TBL] [Abstract][Full Text] [Related]
65. Opisthorchiasis with proinflammatory cytokines (IL-1β and TNF-α) polymorphisms influence risk of intrahepatic cholangiocarcinoma in Thailand: a nested case-control study.
Promthet S; Songserm N; Woradet S; Pientong C; Ekalaksananan T; Wiangnon S; Ali A
BMC Cancer; 2018 Aug; 18(1):846. PubMed ID: 30139338
[TBL] [Abstract][Full Text] [Related]
66. Diabetes-associated dysregulated cytokines and cancer.
Wu Y; Liu Y; Dong Y; Vadgama J
Integr Cancer Sci Ther; 2016 Feb; 3(1):370-378. PubMed ID: 29930868
[TBL] [Abstract][Full Text] [Related]
67. Association of Interleukin-2-330T/G and Interleukin-10-1082A/G Genetic Polymorphisms with B-Cell Non-Hodgkin Lymphoma in a Cohort of Egyptians.
Abdel Rahman HA; Khorshied MM; Reda Khorshid OM; Mourad HM
Turk J Haematol; 2018 May; 35(2):99-108. PubMed ID: 28713071
[TBL] [Abstract][Full Text] [Related]
68. Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics.
Espinoza JA; Jabeen S; Batra R; Papaleo E; Haakensen V; Timmermans Wielenga V; Møller Talman ML; Brunner N; Børresen-Dale AL; Gromov P; Helland Å; Kristensen VN; Gromova I
Oncoimmunology; 2016; 5(12):e1248015. PubMed ID: 28123884
[TBL] [Abstract][Full Text] [Related]
69. Association of IL10 -819C>T and -592C>A Polymorphisms with Non-Hodgkin Lymphoma Susceptibility: Evidence from Published Studies.
Zhang T; Xie S; Zhu JH; Li QW; He J; Zeng AP
J Cancer; 2015; 6(8):709-16. PubMed ID: 26185532
[TBL] [Abstract][Full Text] [Related]
70. Cytokines, chemokines, and chemokine receptors quantitative expressions in patients with ovarian cancer.
Rezaeifard S; Razmkhah M; Robati M; Momtahan M; Ghaderi A
Iran J Med Sci; 2015 May; 40(3):225-32. PubMed ID: 25999622
[TBL] [Abstract][Full Text] [Related]
71. Association of the four common polymorphisms in interleukin-10 (rs1800890, rs1800896, rs1800871, and rs1800872) with non-Hodgkin's lymphoma risk: a meta-analysis.
Dai ZM; He AL; Zhang WG; Liu J; Cao XM; Chen YX; Ma XR; Zhao WH; Dai ZJ
Int J Clin Exp Med; 2014; 7(12):4720-33. PubMed ID: 25663969
[TBL] [Abstract][Full Text] [Related]
72. The relationship of T helper-2 pathway components interleukin-4, interleukin-10, immunoglobulin e, and eosinophils with prognostic markers in non-hodgkin lymphoma: a case-control study.
Güler N; Kelkitli E; Atay H; Erdem D; Alaçam H; Bek Y; Özatlı D; Turgut M; Yıldız L; Yücel İ
Turk J Haematol; 2014 Dec; 31(4):381-7. PubMed ID: 25541655
[TBL] [Abstract][Full Text] [Related]
73. The modified Glasgow Prognostic Scores as a predictor in diffuse large B cell lymphoma treated with R-CHOP regimen.
Kim Y; Kim SJ; Hwang D; Jang J; Hyun SY; Kim YR; Kim JS; Min YH; Cheong JW
Yonsei Med J; 2014 Nov; 55(6):1568-75. PubMed ID: 25323893
[TBL] [Abstract][Full Text] [Related]
74. Chronic inflammation and cytokines in the tumor microenvironment.
Landskron G; De la Fuente M; Thuwajit P; Thuwajit C; Hermoso MA
J Immunol Res; 2014; 2014():149185. PubMed ID: 24901008
[TBL] [Abstract][Full Text] [Related]
75. The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma.
Kimball AS; Webb TJ
Mol Cell Pharmacol; 2013 Jan; 5(1):27-38. PubMed ID: 24648864
[TBL] [Abstract][Full Text] [Related]
76. Cancer-related inflammation.
Candido J; Hagemann T
J Clin Immunol; 2013 Jan; 33 Suppl 1():S79-84. PubMed ID: 23225204
[TBL] [Abstract][Full Text] [Related]
77. Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder.
Lang F; Linlin M; Ye T; Yuhai Z
J Clin Lab Anal; 2012 Sep; 26(5):365-71. PubMed ID: 23001982
[TBL] [Abstract][Full Text] [Related]
78. The IL-10 promoter haplotype and cancer risk: evidence from a meta-analysis.
Zhang K; Zhang L; Wang X; Zhang L
Fam Cancer; 2012 Sep; 11(3):313-9. PubMed ID: 22644143
[TBL] [Abstract][Full Text] [Related]
79. IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas.
Ramkumar HL; Shen DF; Tuo J; Braziel RM; Coupland SE; Smith JR; Chan CC
Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1541-8. PubMed ID: 22628023
[TBL] [Abstract][Full Text] [Related]
80. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer.
Hart KM; Byrne KT; Molloy MJ; Usherwood EM; Berwin B
Front Immunol; 2011; 2():29. PubMed ID: 22566819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
